Form 4: Anika Therapeutics CEO Cheryl Blanchard Reports Stock Transactions
SEC Form 4 Filing
Cheryl Blanchard, CEO of Anika Therapeutics, reports the vesting of RSUs and related stock transactions.
Summary
- Cheryl Blanchard, the CEO and a Director of Anika Therapeutics, reported transactions related to the vesting of Restricted Stock Units (RSUs).
- On March 17, 2025, 25,132 shares were acquired upon the vesting of RSUs, settled in shares.
- 12,152 shares were withheld by the issuer to cover tax obligations related to the RSU vesting.
- Dr. Blanchard transferred 11,742 shares to The Cheryl R. Blanchard Amended and Restated Revocable Trust.
- She was also granted 73,559 and 71,403 new RSUs on March 14, 2025, which vest in installments or upon achievement of certain market metrics.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing stock transactions. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.
Future Outlook
The 73,559 RSUs vest in three equal annual installments beginning March 14, 2026. The 71,403 performance-based RSUs cliff vest on the 3rd anniversary of the grant date, subject to the Compensation Committee's determination of achievement of the award prior to the vest date.
Industry Context
This filing is a routine disclosure of stock transactions by a company executive, common in publicly traded companies. It provides transparency into the executive's holdings and transactions in the company's stock.
Comparison to Industry Standards
- Form 4 filings are standard practice for corporate insiders in publicly traded companies, as mandated by the SEC.
- The vesting schedules and terms of the RSUs are typical compensation structures used to incentivize and retain key executives.
- Similar filings can be observed for executives at comparable companies in the biotechnology and medical device industries, such as Zimmer Biomet, Stryker, and Medtronic.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the change in ownership of shares.
- The vesting of RSUs incentivizes the CEO to perform well, potentially benefiting shareholders.
Key Dates
| Date | Description |
|---|---|
| 2014-12-19 | Date of The Cheryl R. Blanchard Amended and Restated Revocable Trust |
| 2024-03-15 | Date of phantom RSU grant |
| 2025-03-14 | Date of RSU grants and the trading day prior to which the vesting of RSUs gave rise to tax withholding obligations |
| 2025-03-15 | Date RSUs vested |
| 2025-03-17 | Date of stock transactions (RSU vesting and tax withholding) |
| 2025-03-18 | Date of Form 4 filing |
| 2026-03-14 | First vesting installment of 73,559 RSUs |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.